Rimonabant: Managing Multiple Cardiometabolic Risk Factors

Rimonabant: New therapeutic option for managing cardiometabolic risk

Download VBWG06_Rimonabant.ppt (12 slides - 1.0MB)

Rimonabant:New therapeutic option for managing cardiometabolic risk Unmet needs in obesity and the metabolic syndrome Endocannabinoid system (ECS): Overview Implications of CB1 receptor activation Overview of rimonabant clinical trial programs for the treatment of multiple cardiometabolic risk factors Rimonabant In Obesity (RIO) program RIO clinical trial program: Efficacy overview Significant decrease in metabolic syndrome RIO clinical trial program: Safety and tolerability overview Rimonabant: No significant effect on mood Rimonabant: RIO program summary Rimonabant: Therapeutic potential


Related at vwbg.org

Core Curriculum

Contemporary Management of Cardiometabolic Risk

View/Download individual slides (105 Slides)

RIO-Diabetes trial: Rimonabant In Obesity

View/Download individual slides (13 Slides)
More related